Boule Diagnostics (BOUL) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales were SEK 130.4 million, down 6.6% year-over-year, with a 2% organic decline and negative currency effects.

• OEM segment delivered strong growth, with sales up 51%, partially offsetting lower instrument and consumable sales.

• Adjusted EBIT surged 93.7% to SEK 15.3 million, with margin rising to 11.8% from 5.7%.

• Significant restructuring initiatives underway, targeting SEK 16 million in annual savings.

• Major one-time costs included a SEK 265 million impairment on the BM900 project and SEK 27 million write-down of Russian assets.

Financial highlights

• Adjusted gross profit increased 6.1% to SEK 61.3 million; gross margin improved to 47% from 41.4%.

• Cash flow from operating activities was SEK 5.2 million in Q3; available liquidity at quarter-end was SEK 48 million.

• Net cash/EBIT (R12) was -0.1; net cash position at -19.9 MSEK.

• Investments in new technology and product development totaled up to SEK 16.5 million in Q3.

• Deferred tax asset of SEK 51.2 million recognized, mainly from asset impairments.

Outlook and guidance

• Manufacturing ramp-up in India on track for Q4 2024; BM950 performance evaluation scheduled for H1 2025.

• Commercialization of new 5-part system targeted for 2026.

• Investments for Q4 2024 expected at SEK 25 million; full-year 2025 investments to drop to SEK 45 million.

• Positive cash flow targeted for 2025, with Q4 2024 cash flow possibly still negative due to high investment rate.

• Long-term financial targets: operating margin >15%, sales growth >10%, net debt/EBIT <3x.